Early Phase Evaluation of Intravesical Erdafitinib in NMIBC

In a recent discussion, Dr. Antoni Vilaseca Cabo, MD, an adjunct physician at Hospital Clínic de Barcelona, shed light on a novel approach to treating bladder cancer by targeting specific genetic alterations directly within the bladder. His insights center on the prevalence of FGFR alterations in a significant subset of bladder cancer patients and the innovative strategy of repurposing an existing drug to address them locally.

Dr. Vilaseca Cabo explained that FGFR alterations are remarkably common in bladder cancer. They are found in approximately 70 percent of patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC) and in around 40% of those with high-risk NMIBC. This high prevalence makes FGFR a compelling therapeutic target. Currently, erdafitinib, an FGFR inhibitor, is already approved for the systemic treatment of patients with metastatic urothelial carcinoma. Leveraging this existing therapy, Dr. Vilaseca Cabo and his team are investigating its application in a completely new way.

The innovative method involves using a device called TAR-210, an intravesical drug delivery system designed to continuously release erdafitinib directly into the bladder. This targeted approach allows for high concentrations of the drug to be delivered precisely where they are needed most, while potentially minimizing the systemic side effects associated with oral administration. Dr. Vilaseca Cabo highlighted the significance of this research, noting that it represents the first time a mutation-directed therapy has been reported in NMIBC. This marks a substantial step forward in the pursuit of personalized medicine for these patients.

The ultimate goal of this bladder-sparing strategy is to provide patients with an effective oncological treatment that avoids the toxicity of more radical interventions. By preserving the patient's own bladder, this approach aligns with a core desire in urologic oncology: to offer therapies that are both therapeutically beneficial and maintain the patient's quality of life. This research opens a new frontier for treating NMIBC, offering a potential future where treatment is tailored to the genetic profile of the tumor and delivered in the least invasive manner possible.